Janus Henderson Group PLC Chemo Centryx, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $2.72 Million - $6.36 Million	122,785 Added 1233.52%	132,739 $6.86 Million
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $875 - $1,568	57 Added 0.58%	9,954 $246,000
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $22 - $39	1 Added 0.01%	9,897 $248,000
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $181,888 - $400,788	9,896 New	9,896 $361,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.